A large swath of insured Americans could be eligible for a popular class of weight loss and diabetes drugs. Meanwhile, Apple announces new health features.
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox.Good afternoon! A large swath of insured Americans could be eligible for a highly popular class of weight loss and diabetes medications called GLP-1s, such asAt least two in five U.S.
"We're incredibly proud to introduce a first-of-its-kind Hearing Aid feature, coming this fall with AirPods Pro 2, plus an innovative way to detect signs of sleep apnea with Apple Watch," Apple CEO Tim Cook wrote in a post on X onApple said its latest watch can help alert users to sleep apnea, a sleep disorder that can cause a person's breathing to repeatedly start and stop throughout the night.
The Series 10 launches Sept. 20, but it's already available for preorder. It starts at $399. Sleep apnea notifications will also be available on the Apple Watch Series 9 and Ultra 2. Apple said the test is clinically validated and designed based on real-world data. The results will be stored in the Health app, where users will see their personalized hearing profile. People can take the test regularly and access educational materials about hearing loss, the company added.
Additionally, Desai said users' hearing profiles are automatically applied to phone calls, music and movies across their Apple devices.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Healthy Returns: More than 50 million privately insured adults could be eligible for GLP-1 drugsA large swath of insured Americans could be eligible for a popular class of weight loss and diabetes drugs. Meanwhile, Apple announces new health features.
Read more »
Healthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug marketEli Lilly may be starting to gain an edge over Novo Nordisk in the GLP-1 market. Meanwhile, Stryker will acquire artificial intelligence startup Care.ai.
Read more »
Healthy Returns: Eli Lilly gains momentum against Novo Nordisk in the weight loss drug marketEli Lilly may be starting to gain an edge over Novo Nordisk in the GLP-1 market. Meanwhile, Stryker will acquire artificial intelligence startup Care.ai.
Read more »
Healthy Returns: The race to develop combination shots targeting Covid, flu is heating upPfizer faced a setback with its combo Covid-flu shot, which could allow Moderna and others to gain ground. Meanwhile, Epic’s UGM meeting is underway.
Read more »
Healthy Returns: What to know about the latest round of Pfizer, Moderna Covid vaccinesA brand new round of Covid shots from Pfizer and Moderna is about to reach Americans. Meanwhile, CNBC tested out Dexcom’s new CGM Stelo.
Read more »
Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stockEli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter continuous glucose monitor in U.S.
Read more »